Authors: Vickers RJ, Bassetti M, Clancy CJ, Garey KW, Greenburg D, Nguyen M, Roblin D, Tillotson GS, Wilcox MH
Despite the global health threat of antimicrobial resistance, currently the commercial model for antibiotic development does not offer a return on investment, leading to a lack of interest from pharmaceutical companies and very few candidates in the clinical pipeline.
In this perspective piece for Future Microbiology the authors argue that, in addition to a lack of investment, there is a lack of innovation to meet the current shortcomings of antibiotic R&D, discussing the role stewardship could play in revitalizing innovation, the need to move away from a budget-dominated view of antibiotic use, and the increasing interdisciplinary nature of antimicrobial control programs.
You might also like:
